Response by Bagai et al to Letter Regarding Article, “Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We agree with Dr Petrie that, in some patients, concerns regarding extended duration of dual antiplatelet therapy (DAPT) are justified. Therefore, we recommend individualizing the duration of DAPT based on ischemic and bleeding risk taken in the context of the setting for DAPT (percutaneous coronary intervention for stable coronary disease versus acute coronary syndrome).1 After acute coronary syndrome, the totality of the evidence favors extended DAPT with reduction in cardiovascular events, including myocardial infarction, ischemic stroke, and death, without an increase in noncardiovascular death, fatal bleeding, or intracranial …